DEERFIELD, Ill. - Baxter International Inc. (NYSE:BAX), a global medical products company, has launched five new injectable products in the United States, expanding its Pharmaceuticals portfolio. The products are designed to meet critical needs in therapeutic areas such as anti-infective and anti-hypotensive medications.
The new offerings include a ready-to-use Norepinephrine Bitartrate in 5% Dextrose Injection for severe, acute hypotension, now available in three strengths including a new 16 mg/250 mL option. Baxter claims this to be the first and only FDA-approved ready-to-use formulation of its kind.
Another addition is Vasopressin in 0.9% Sodium Chloride Injection, also presented as the first FDA-approved ready-to-use vasopressin in a flexible container, available in two strengths. This product is indicated for adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Baxter has also introduced Vancomycin Injection, USP in 5% Dextrose in two new strengths, marking the company's first frozen ready-to-use offerings in 250 mL and 300 mL volumes. Vancomycin is used for serious infections caused by methicillin-resistant staphylococci.
The company now offers Ropivacaine Hydrochloride Injection, USP in a ready-to-use, single-dose infusion bag for local or regional anesthesia and acute pain management. Additionally, Baxter has released a Regadenoson Injection pre-filled syringe, a coronary vasodilator for pharmacologic stress testing.
These products aim to provide operational efficiencies for healthcare providers by offering ready-to-use formats of standard concentrations, which may reduce the risk of contamination and potential errors associated with manual compounding.
The information is based on a press release statement from Baxter International Inc.
InvestingPro Insights
Baxter International Inc. (NYSE:BAX) continues to strengthen its position in the healthcare market with the launch of new injectable products. In light of these developments, key financial metrics and InvestingPro Tips offer insights into the company's performance and future outlook.
InvestingPro data shows that Baxter has a market capitalization of $21.39 billion and a Price/Earnings (P/E) ratio of 7.97, indicating investor confidence in the company's earnings potential. Additionally, the company has maintained a strong commitment to shareholder returns, as evidenced by a dividend yield of 2.75% and a record of raising its dividend for 7 consecutive years. This consistent performance is a testament to Baxter's robust business model in the competitive Healthcare Equipment & Supplies industry.
Another notable InvestingPro Tip is that Baxter has experienced a large price uptick over the last six months, with a 31.0% total price return, highlighting the market's positive reaction to the company's strategic moves, including the expansion of its Pharmaceuticals portfolio.
For readers interested in further analysis, there are more InvestingPro Tips available, providing a comprehensive understanding of Baxter's financial health and market position. To explore these additional insights, visit Investing.com/pro/BAX and remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.